Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

not_yet_recruiting150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_3

Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

NCT07486024
completedphase_3

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

NCT04062201

Clinical Trials (2)

Showing 2 of 2 trials
NCT07486024Phase 3

Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

Not Yet Recruiting
NCT04062201Phase 3

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2